Background: Most intensive care unit (ICU) patients receive broad-spectrum antibiotics. While lifesaving in some, in others these treatments may be unnecessary and place patients at risk of antibioticassociated harms. Objectives: To review the literature exploring how we diagnose infection in patients in the ICU and address the safety and utility of a 'watchful waiting' approach to antibiotic initiation with selected patients in the ICU. Sources: A semi-structured search of PubMed and Cochrane Library databases for articles published in English during the past 15 years was conducted. Content: Distinguishing infection from non-infectious mimics in ICU patients is uniquely challenging. At present, we do not have access to a rapid point-of-care test that reliably differentiates between individuals who need antibiotics and those who do not. A small number of studies have attempted to compare early aggressive versus conservative antimicrobial strategies in the ICU. However, this body of literature is small and not robust enough to guide practice. Implications: This issue will not likely be resolved until there are diagnostic tests that rapidly and reliably identify the presence or absence of infection in the ICU population. In the meantime, prospective trials that identify clinical situations wherein it is safe to delay or withhold antibiotic initiation in the ICU until the presence of an infection is proven are warranted. K.J. Denny, Clin Microbiol Infect 2020;26:35 
Introduction
Prescribing broad-spectrum empiric antibiotics 'just in case' is the norm in the intensive care unit (ICU) [1] . An international pointprevalence study has demonstrated that, on a given day, 70% of all patients in ICUs are administered at least one antibiotic [2] . On the one hand, antibiotics are life-saving therapies in infected patients, but they do not benefit non-infected patients and place them at risk for potential antibiotic-associated adverse events.
Antibiotic-associated harms include adverse drug events, risk of secondary opportunistic infections and antimicrobial resistance [3e6] . Antibiotic-associated adverse drug events are common in ICU patients, due partly to the underlying critical illness that increases susceptibility to organ injury [4] , as well as the multiplicity of medications that ICU patients receive, which increase the risk of undesirable drug interactions [5] .
The individual and collective ecological harms of antibiotics are well documented in the ICU [7] . Certain classes of antibiotics commonly used in the ICU have a propensity to cause ecological 'collateral damage' through a loss of microbial diversity and selection for organisms such as Clostridioides difficile and Candida spp. that can cause secondary infection [8e13] . Further, a significant increase in the carriage of resistant bacteria has been demonstrated to occur with even brief antibiotic exposure (1e3 days) in ICU patients [14] .
Antibiotic de-escalation has been proposed as a potential compromise to address the competing goals of rapid and effective treatment of potential infection and reducing antibiotic overuse and resultant unnecessary antibiotic harms [15] . However, strong evidence demonstrating that antibiotic de-escalation is a reliable strategy in patients in the ICU is lacking, partly because of a lack of a clear definition of what de-escalation involves. Antibiotic deescalation strategies have not yet been shown to be effective in reducing the carriage of multidrug-resistant bacteria and it may increase the incidence of secondary infections [16, 17] .
We therefore propose that the ideal approach, if proven safe, would be to avoid initiation of antibiotics in the ICU patient until the treating clinician were convinced of the presence of infection and its source. The following narrative review aims to explore the literature that addresses how we diagnose infection in the ICU and whether clinicians working with ICU patients can confidently employ a 'watchful waiting' strategy, with the resultant benefit of avoiding unnecessary antibiotic exposure, and hence harms.
There have been previous reviews that have addressed how to reduce antibiotic exposure in ICU patients [18e21]. Our narrative review attempts to specifically focus on the question of how to avoid the initiation of antibiotics in the high stakes environment of the ICU.
Methods
A literature search using the PubMed and Cochrane Library databases for published English-language articles within the past 15 years was conducted by one of the authors (KJD). Relevant additional articles identified ad hoc by all authors were also included.
The following types of articles were included: randomized controlled trials, meta-analyses, observational (small and large), expert opinions, and guidelines. Search terms included were 'intensive care' AND '(antibiotics OR antimicrobials)' AND (overuse OR empiric OR delayed OR conservative OR timing OR culture negative OR biomarkers OR unnecessary OR inappropriate). The initial search strategy identified 2747 results, those deemed to be relevant to this narrative review on when not to start antibiotics in the ICU were included.
Does this patient in the ICU have an infection?
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated response to infection [22] . However, although identifying organ dysfunction is relatively straightforward, prospectively diagnosing infection as the cause of organ dysfunction is more challenging. The difficulty in the bedside diagnosis of sepsis was highlighted by a cohort study in the Netherlands, where of 2579 individuals who presented to the ICU with clinically suspected sepsis, 13% had a post hoc infection likelihood of 'none' and an additional 30% were 'possible' [23] .
Diagnosing infectious complications in existing ICU patients is fraught with problems. Clinical signs (e.g. pyrexia, tachycardia, vasoplegia) and laboratory findings (e.g. leucocytosis/leucopenia, hyperlactataemia), which are often attributed to infection, are commonly associated with non-infectious aetiologies in the ICU population [24e28] . Even clinical signs that may suggest a specific source of infection (e.g. lung consolidation, increased sputum production) may be non-specific in ventilated ICU patients [29] .
Microbiological cultures are the current reference standard for confirming infection and a positive culture, ideally with input from a clinical microbiologist, facilitates the administration of appropriate antibiotics. However, current bacterial and fungal culture techniques take time (typically >24 hours), necessitate good (and sometimes invasive) sampling techniques, and there is the potential for patient deterioration while waiting for results. Even once culture results are obtained, the retrospective diagnosis of sepsis can be problematic because of contamination, colonization and 'culture-negative' infection. In patients admitted to the ICU, 28%e49% of patients with a syndrome consistent with likely sepsis have negative cultures [30e34]. Failure to identify an organism may be a result of the patient receiving antibiotics previously, so obscuring conventional cultures, poor collection technique, or the presence of unusual or slow-growing organisms [35, 36] . Alternatively, the patient may have a non-infectious cause for their clinical syndrome. For these reasons, even the retrospective diagnosis of infection is problematic, as demonstrated in a study by Rhee et al. [37] in which poor inter-rater reliability (Fleiss's k ¼ 0.21) was exhibited by critical care clinicians when asked to in diagnose sepsis using a series of case vignettes.
There has been increasing interest in exploring novel diagnostics that can quickly and accurately differentiate between those patients with and without infection. Diagnostics can be broadly differentiated into two groups: (i) diagnostics that identify the presence of microbes, and (ii) biomarkers that identify the host response to the presence of microbes. Assays that aim to identify the presence of microbes faster than conventional microbiological cultures are in various stages of development [38e40]. However, these assays remain susceptible to the problems of contamination and colonization, leading to the identification of microorganisms that are not necessarily responsible for patient deteriorationdproblems that may or may not be solved with emerging next-generation sequencing diagnostic technology [41] .
Host biomarkers have shown varying levels of promise in guiding antibiotic use in the ICU environment [42e44]. Procalcitonin has been shown to be helpful in reducing the duration of antibiotic therapy, albeit this reduction is often modest [45] . Other proposed biomarkers of sepsis include C-reactive protein [46, 47] , various cytokines [48, 49] , adhesion molecules [50] , hormones [51] , receptors [52e55], and surface glycoproteins [56] . There is also increasing interest in the role of '-omic' technologies (genomics, metabolomics, transcriptomic, proteomic) in the diagnosis of sepsis [57] . However, the utility of currently available host biomarkers in distinguishing between ICU patients with and without infection, and so guiding antibiotic initiation, remains low [7,44,58e63] .
It is hypothesized that, given the biological complexity of sepsis, a stratification strategy based on a panel of multiple biomarkers such as gene expression has more potential to meet the needs of an ideal biomarker-based stratification tool [27, 64, 65] . Such biomarker tests remain in their infancy and we await prospective studies to determine their utility in clinical practice.
Can we afford to 'watch and wait' for infection in an ICU patient?
While we wait for improved diagnostic tools that allow us to more quickly and accurately identify the presence of infection in patients in the ICU, is it safe to adopt a more conservative approach to antimicrobial prescribing? Is it safe for the treating clinicians to delay empiric broad-spectrum antibiotics in an ICU patient until the likely source of infection or another non-infective diagnosis becomes apparent?
The Surviving Sepsis Campaign guidelines recommend that antibiotics be initiated within 1 hour from recognition of sepsis [66] . However, data investigating this recommendation have been inconsistent, particularly in patients without shock, and suffer from the biases inherent in time-to-intervention trial design (e.g. treatment delay in more complicated patients) [67e72]. Further, many studies in this area lack critical information regarding how infections were confirmed, whether antibiotic selection was appropriate, and/or when (or whether) source control was achieved.
Initial inappropriate antibiotic therapy has been demonstrated to be an independent risk factor for mortality in ICU populations [73e75], where inappropriate was defined retrospectively as empiric antibiotics that were unlikely to treat the causative pathogen. Source control is also vital to preventing increased mortality [76, 77] . In a large prospective observational study by Bloos et al. [76] , there was no mortality benefit from the early initiation of antimicrobial therapyddefined as antibiotic administration that occurs within the first hour of the onset of infection-related organ dysfunction. However, inadequate source control was shown to increase 28-day mortality from 26.7% to 42.9%. We therefore hypothesize that the importance of timeliness with regards to antibiotic administration may be overemphasized, and rather a more nuanced approach wherein brief delays in antibiotic administration to allow for source recognition, source control and ensuring antibiotic appropriateness may be valid.
Further, it is unclear as to whether we should distinguish between patients who are admitted to the ICU with likely infection and those with a critical illness who develop an infection as a secondary complication. Sepsis is not a homogeneous syndrome; it has a phenotype that varies based on both characteristics of the culprit organism and characteristics of the host immune response [78] .
Infections acquired in the ICU are associated with microbiological isolates different from those acquired in the community, and are often associated with resistant organisms [2, 79] . This may be, in part, due to different environmental risk factors (e.g. central vascular catheters, endotracheal tubes), previous exposure to antibiotics (e.g. antimicrobial prophylaxis for surgery), and an altered microbiome characterized by a loss of microbial richness and diversity [80, 81] . The presence of critical illness also results in an altered immunophenotype, characterized by the concurrent upregulation of multiple pro-and anti-inflammatory pathways, with down-regulation of adaptive immune pathways [82] . Of note, the immunophenotypes of critical illness, and associated risk of secondary nosocomial infection, are remarkably similar independent of whether the initial insult had an infectious or non-infectious aetiology [82, 83] .
On the other hand, ICU patients may also have protective factorsdnamely, close monitoring of physiology and one-to-one nursingdthat may mean that 'watchful waiting' in the ICU is a safer strategy compared with other populations. Hranjec et al. [84] attempted to address the safety of delayed initiation of antimicrobial therapy in a cohort of surgical ICU patients by performing a quasi-experimental, before-and-after observational cohort study that compared an aggressive treatment strategy (early antibiotic treatment for suspected infection) with a conservative one (antimicrobial treatment only after objective findings confirmed infection). They concluded that waiting for objective data to diagnose infection before antimicrobial treatment was not associated with increased mortality. However, antibiotic appropriateness was low, with only 62%e74% of patients receiving appropriate antibiotic regimens, and the case-fatality rate was high. Further, patients received prolonged courses of antibiotics (12e17 days), which itself is associated with adverse outcomes [85, 86] .
In another study, Amaral and Holder [87] investigated whether delays in antimicrobial therapy increased mortality in a specific condition in the ICU, ventilator-associated pneumonia. In this single-centre retrospective study, there was no association between timing of antibiotics after the identification of a ventilatorassociated complication and patient harm (mortality, superinfection, or treatment failure) in patients subsequently diagnosed with ventilator-associated pneumonia.
However, the above single-centre studies can only be, at best, hypothesis-generating given their significant and numerous limitations. Future studies are required to determine whether delayed prescribing strategies for selected patients in the ICU setting are safe, feasible and beneficial. In the meantime, we have provided some recommendations for daily practice of antibiotic initiation in the ICU based on expert interpretation of available evidence ( Table 1) .
What future research do we need?
The above narrative review of the literature highlights two key gaps in the evidence that need to be addressed so that clinicians can safely and confidently avoid unnecessary antibiotic initiation in the ICU. First, we need novel diagnostic strategies to help us better identify the presence of infection and, second, we need highquality multi-centre prospective randomized studies to inform us when 'watchful waiting' may be a safe and effective approach in the ICU. Potential future approaches to address these gaps in the literature will be discussed in turn.
Improving our ability to identify infection, and distinguish it from non-infectious mimics, is the ultimate solution to reducing unnecessary antibiotic initiation in the ICU. We propose that an ideal diagnostic tool for infection would quickly, accurately and affordably identify the presence or absence of a specific pathogen, any antibiotic-resistance genes, and a host response to a pathogen [78] . Identifying the host response to infection is necessary to differentiate between colonization or contamination and true infection. An ideal tool would also be able to monitor the response to treatment, and facilitate the cessation of antibiotic treatment [61] . It is essential that any proposed diagnostic tests are evaluated against clinically important outcome measures (e.g. mortality, morbidity).
However, until such a diagnostic tool becomes available that has the sensitivity and specificity to safely distinguish those critically ill patients who need antibiotics from those who do not, we recommend that additional studies are required that aim to determine whether a 'watchful waiting' approach to antibiotic prescribing is both safe and beneficial to selected ICU patients.
Clinical researchers additionally need to consider what are the most practical ICU subgroups in which to trial this approach. We recommend that studies investigating the safety of delayed prescribing: (i) focus on specific subgroups of patients (e.g. trauma, burns, or patients with febrile neutropenia); (ii) exclude patients who are hypotensive because of suspected infection [30] ; and, (iii) Table 1 Recommendations for daily practice in patients with suspected infection the intensive care unit (ICU) based on expert opinion of the authors Recommendations for daily practice Source control in a critically ill patient with sepsis should not be delayed In the non-shocked ICU patient with suspected infection (and onset >48 hours after ICU admission) consider delaying the initiation of antimicrobial therapy until after initial investigations aimed at sepsis diagnosis and source identification In patients with proven infections, do not unnecessarily defer antibiotics Currently available host biomarkers such as C-reactive protein and procalcitonin have no place in routinely guiding the initiation of antibiotics in the ICU initially focus on patients who are already in the closely monitored environment of the ICU who may have developed an infectious complication (versus an initial presenting complaint of possible infection). The latter is recommended because the harms of delayed prescribing in certain populations (e.g. suspected meningococcal meningitis) are likely to be significantly greater than those of others (e.g. ventilator-associated pneumonia). We await further evidence regarding antibiotic initiation in patients in the ICU, but have summarized a suggested approach to the question 'Do I Need to Give Antibiotics?' in Fig. 1 .
Future studies also need to measure and adjust for other important contributors to treatment failure, including: the appropriateness of empiric antibiotic selection [73e75]; the appropriateness of antibiotic dosing based on the unique pharmacokinetic and pharmacodynamic changes seen in ICU patients [7, 88] ; and the timeliness and thoroughness of source control [76, 77] . We hypothesize that, for some subgroups of ICU patients, the benefit of early empiric antimicrobial treatment (versus delayed targeted antimicrobial treatment) is likely to be minimal if appropriate antibiotic selection, adequate dosing and efficient source control are achieved. We have outlined future research strategies and directions in Table 2 .
Conclusions
In the future, we will inevitably have the luxury of a rapid testing and management tool whereby only ICU patients who have an infection will receive antibiotics. However, at present we must continue to integrate the available clinical, laboratory and radiological information to optimize management with nearly all patients with infections receiving antibiotics while minimizing these treatments in non-infected patients. This approach relies heavily on shared decision-making between intensivists and experts in infectious disease and clinical microbiology. The definitive answer to the problem of antibiotic overuse in the ICU is the development of point-of-care diagnostic technologies that will allow for the quick and reliable diagnosis of infection. In the meantime, trials that identify when or if it is safe to delay antibiotic initiation in the ICU until an infection is proven are needed before this approach can be widely implemented.
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